logo

SCIENCE CHINA Life Sciences, Volume 64 , Issue 2 : 330-333(2021) https://doi.org/10.1007/s11427-020-1782-1

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

More info
  • ReceivedMay 10, 2020
  • AcceptedJul 25, 2020
  • PublishedAug 3, 2020

Abstract

There is no abstract available for this article.


Funded by

the National Key R&D Program of Ministry of Science and Technology of China(2020YFC0844500)

National Natural Science Foundation of China(31130031)

Emergency Project Fund of Chinese Academy of Sciences(2020YJFK0105)

and Chinese Academy of Engineering and Ma Yun Foundation(2020-CMKYGG-05)


Acknowledgment

We thank all medical staff and medical data managers for data extraction and help for analysis. We would like to thank Prof. Eric H. Xu at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for his useful suggestion and language improvement in writing this paper. This work was supported in part by the National Key R&D Program of Ministry of Science and Technology of China (2020YFC0844500), National Natural Science Foundation of China (31130031), Emergency Project Fund of Chinese Academy of Sciences (2020YJFK0105), and Chinese Academy of Engineering and Ma Yun Foundation (2020-CMKYGG-05).


Interest statement

The author(s) declare that they have no conflict of interest.


Supplement

SUPPORTING INFORMATION

The supporting information is available online at https://doi.org/10.1007/s11427-020-1782-1. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.


References

[1] Chen, C., Chen, C., Yan, J.T., Zhou, N., Zhao, J.P., and Wang, D.W. (2020). Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19 (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 48, E008. Google Scholar

[2] Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382: 1708-1720 CrossRef PubMed Google Scholar

[3] Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z.. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020, 5: 811 CrossRef PubMed Google Scholar

[4] Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G.. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 2020, 58: 1021-1028 CrossRef PubMed Google Scholar

[5] Huang W., Li C., Wang Z., Wang H., Zhou N., Jiang J., Ni L., Zhang X.A., Wang D.W.. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. Sci China Life Sci, 2020, : https://doi.org/10.1007/s11427-020-1733-4 CrossRef PubMed Google Scholar

[6] Ledford H.. How does COVID-19 kill? Uncertainty is hampering doctors’ ability to choose treatments. Nature, 2020, 580: 311-312 CrossRef PubMed ADS Google Scholar

[7] Liu, C., Jiang, Z.C., Shao, C.X., Zhang, H.G., Yue, H.M., Chen, Z.H., Ma, B.Y., Liu, W.Y., Huang, H.H., Yang, J., et al. (2020). Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study (in Chinese). Zhonghua Gan Zang Bing Za Zhi 28, 148–152. Google Scholar

[8] Liu W., Tao Z.W., Wang L., Yuan M.L., Liu K., Zhou L., Wei S., Deng Y., Liu J., Liu H.G., et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J, 2020, 133: 1032-1038 CrossRef PubMed Google Scholar

[9] Ni L., Zhou L., Zhou M., Zhao J., Wang D.W.. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med, 2020, 14: 210-214 CrossRef PubMed Google Scholar

[10] Saqrane S., El Mhammedi M.A.. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New Microb New Infect, 2020, 35: 100680 CrossRef PubMed Google Scholar

[11] Yu B., Li C., Chen P., Zhou N., Wang L., Li J., Jiang H., Wang D.W.. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci, 2020, : https://doi.org/10.1007/s11427-020-1732-2 CrossRef PubMed Google Scholar

  • Figure 1

    HCQ treatment exerted some changes. A, In all the COVID-19 patients, IL-6 levels significantly reduced after HCQ treatment, *P<0.05. IL-6 levels were elevated after HCQ withdrawal in the HCQ group patients. B, In the non-critically ill patients, IL-6 levels were significantly reduced after 10 days of HCQ treatment, *P<0.05. C, In critically ill patients, albumin levels were significantly elevated after HCQ treatment, *P<0.05. D, In the non-critically ill patients, albumin levels were also significantly elevated after HCQ treatment, *P<0.05. E, In the critically ill patients treated with HCQ, NT-proBNP levels were significantly reduced, *P<0.05, whereas in the NHCQ group patients, NT-proBNP levels were elevated. F, In almost all the non-critically ill patients, NT-proBNP levels were below the upper limit of the normal range. G, In the critically ill patients treated with HCQ, cTnI levels were reduced; furthermore, cTnI levels of the HCQ group patients were significantly lower than those of the NHCQ group patients after 20 days of HCQ treatment, *P<0.05. H, In almost all the non-critically ill patients, cTnI levels were below the upper limit of the normal range. Data are presented as medians and interquartile ranges (Q1–Q3). HCQ, hydroxychloroquine; NHCQ, non-hydroxychloroquine; IL, interleukin; ALB, albumin; NT-proBNP, amino-terminal pro-brain natriuretic peptide; cTnI, cardiac troponin I.

qqqq

Contact and support